PT  - JOURNAL ARTICLE
AU  - Matthew Moll
AU  - Brian D. Hobbs
AU  - Aravind Menon
AU  - Auyon J. Ghosh
AU  - Rachel K. Putman
AU  - Takuya Hino
AU  - Akinori Hata
AU  - Edwin K. Silverman
AU  - John Quackenbush
AU  - Peter J. Castaldi
AU  - Craig P. Hersh
AU  - Michael J. McGeachie
AU  - Don D. Sin
AU  - Ruth Tal-Singer
AU  - Mizuki Nishino
AU  - Hiroto Hatabu
AU  - Gary M. Hunninghake
AU  - Michael H. Cho
TI  - Blood Gene Expression Risk Profiles and Interstitial Lung Abnormalities: COPDGene and ECLIPSE cohort studies
AID  - 10.1101/2022.01.31.22270173
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.31.22270173
4099  - http://medrxiv.org/content/early/2022/02/01/2022.01.31.22270173.short
4100  - http://medrxiv.org/content/early/2022/02/01/2022.01.31.22270173.full
AB  - Rationale Interstitial lung abnormalities (ILA) are radiologic findings that may progress to idiopathic pulmonary fibrosis (IPF). Blood gene expression profiles can predict IPF mortality, but whether these same genes associate with ILA and ILA outcomes is unknown.Objectives To evaluate if a previously described blood gene expression profile associated with IPF mortality is associated with ILA and all-cause mortality.Methods In COPDGene and ECLIPSE study participants with visual scoring of ILA and gene expression data, we evaluated the association of a previously described IPF mortality score with ILA and mortality. We also trained a new ILA score, derived using genes from the IPF score, in a subset of COPDGene. We tested the association with ILA and mortality on the remainder of COPDGene and ECLIPSE.Measurements and Main Results In 1,469 COPDGene (training n=734; testing n=735) and 571 ECLIPSE participants, the IPF score was not associated with ILA or mortality. However, an ILA score derived from IPF score genes was associated with ILA (meta-analysis of test datasets OR 1.4 [95% CI: 1.2-1.6]) and mortality (HR 1.25 [95% CI: 1.12-1.41]). Six of the 11 genes in the ILA score had discordant directions of effects compared to the IPF score. The ILA score partially mediated the effects of age on mortality (11.8% proportion mediated).Conclusions An ILA gene expression score, derived from IPF mortality-associated genes, identified genes with concordant and discordant effects on IPF mortality and ILA. These results suggest shared, and unique biologic processes, amongst those with ILA, IPF, aging, and death.What is the key question Interstitial lung abnormalities (ILA) are radiologic findings that may progress to idiopathic pulmonary fibrosis (IPF). Do blood gene expression profiles that predict IPF mortality also associate with ILA?What is the bottom line An ILA gene expression score, derived from IPF mortality-associated genes, was associated with ILA and all-cause mortality. This score identified genes with concordant and discordant effects on IPF mortality and ILA. Our results suggest shared, and unique biologic processes, amongst those with ILA, IPF, aging, and death.Why read on Our results lend insight into how gene expression profiles and biological pathways associated with IPF prognosis relate to ILA and all-cause mortalityCompeting Interest StatementEKS received grant support from GlaxoSmithKline and Bayer. CPH reports grant support from Boehringer-Ingelheim, Novartis, Bayer and Vertex, outside of this study. MN has received research grants to the institution from AstraZeneca, Daiichi Sankyo, Canon Medical Systems, and has served as a consultant to AstraZeneca, and Daiichi Sankyo. PJC has received grant support from GlaxoSmithKline and Bayer and consulting fees from GlaxoSmithKline and Novartis. RTS was employed by GlaxoSmithKline until 2019 and is a shareholder of GlaxoSmithKline stock; RTS received consulting fees from Immunomet, ENA Respiratory, Teva, and Vocalis Health; she is currently a Board Member of ENA Respiratory on behalf of the COPD Foundation. JQ is on the scientific advisory boards of Caris Life Sciences and Renalytix. HH received grants from Canon Medical Systems Inc and Konica-Minolta Inc. and served as consultant for Mitsubishi Chemical Co and Canon Medical Systems Inc outside of this study. GMH has performed consulting work for Boehringer-Ingelheim, and the Gerson Lehrman Group within the last 3 years. MHC has received grant support from GlaxoSmithKline and Bayer, consulting fees from Genentech and AstraZeneca, and speaking fees from Illumina.Funding StatementMM and AJG are supported by T32HL007427. BDH is supported by NIH K08HL136928 and U01 HL089856. CPH is supported by NIH R01HL130512, R01HL157879 and P01HL114501. PJC is supported by NIH R01HL124233 and R01HL147326. EKS is supported by NIH R01 HL137927, R01 HL147148, U01 HL089856, R01 HL133135, R01 HL152728, P01 HL132825, and P01 HL114501. HH is supported by NIH R01CA203636, 5U01CA209414, NIH/NHLBI 2R01HL111024, NIH R01HL135142, and NIH/NHLBI 1R01HL130974. MN is supported by R01CA203636, U01CA209414, R01HL111024. GMH is supported by NIH R01 HL111024, R01 HL130974, and R0135142. MHC is supported by NIH R01HL137927, R01HL135142, HL147148, and HL089856. The COPDGene project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion. The ECLIPSE study (NCT00292552; GSK code SCO104960) was funded by GlaxoSmithKline. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COPDGene and ECLIPSE studies were approved by local IRB and ethics committees at each institution. The inclusion of COPDGene and ECLIPSE studies in the current study was approved by the Brigham and Women's Hospital IRB (2007P000554).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and access to raw data are available upon reasonable request to the authors